Drug Safety

My favorite three presentations from day 4 at ACR 2021 included the following: Breakthrough Infections in Rheumatic Disease Patients Late-Breaking Abstract L16 - Dr. Jazvinder Singh presented the…

Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: Secukinumab Efficacy in Enthesitis-Related and Juvenile Psoriatic Arthritis. Abstract 1424 – Dr. Hermine…

Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions? The NOR-DRUM trials (A and B) are the first randomized trials to assess…

Psoriatic arthritis is currently experiencing a burgeoning selection of treatment options. As a small sample of novel agents demonstrating efficacy in PsA presented at ACR Convergence 2021, we have…

The third day of ACR 2021 took a big leap in online content.  Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty.  Gender and…

Highlight reports from Sunday, Day 2 at ACR Convergence included: VITAL Trial: Vitamin D and n-3 Fatty Acid Supplements Protect Against Autoimmune Disease Abstract 0957  – Dr. Karen…

Methotrexate may be a rheumatologist’s best friend, but a key part of counselling any patient about its use has always been the risk of hepatotoxicity. Despite methotrexate’s near-ubiquitous use in…

Januse kinase (JAK) inhibitors are targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs) that have risen in popularity as earlier treatment options for rheumatoid arthritis. With…

The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest…

The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and…